# INVA catalysts: Innoviva, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/inva/catalysts

> Innoviva, Inc. (INVA) has no upcoming catalysts in this calendar. The latest recorded is the Innoviva, Inc. earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Innoviva, Inc. |
| Ticker | INVA (Nasdaq) |
| SEC CIK | 1080014 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/inva |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [Carbapenem topline data readout](https://sec-api.dev/pdufa/carbapenem) | INVA | with carbapenem-resistant Acinetobacter infections, with positive top-line data | completed, positive | "We completed ATTACK, a Phase 3 registration trial of XACDURO® for the treatment of patients with carbapenem-resistant Acinetobacter infections, with positive top-line data announced in October 2021 and published in The Lancet Infectious Diseases in May 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm)) |
| May 2023 | [XACDURO (xacduro) FDA approval](https://sec-api.dev/pdufa/xacduro) | INVA |  | completed, approved | "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1080014/000119312526447384/inva-20260930.htm)) |
| May 23, 2023 | [Durlobactam FDA approval](https://sec-api.dev/pdufa/durlobactam) | INVA |  | completed, approved | "XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the FDA on May 23, 2023, and we commenced U.S. commercial sales of XACDURO® in the third quarter of 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm)) |
| Nov 2023 | [Fluoroquinolone topline data readout](https://sec-api.dev/pdufa/fluoroquinolone) | INVA |  | completed, positive | "In November 2023, we reported positive top-line data results of a pivotal Phase 3 trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm)) |
| February 26, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Calif. - February 26, 2025 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/tm257428d1_ex99-1.htm)) |
| mid-2025 | [ZEVTERA® (ceftobiprole) NDA/BLA submission](https://sec-api.dev/pdufa/ceftobiprole) | INVA | uncomplicated gonorrhea | scheduled | ""Looking ahead, we anticipate another strong year in 2025 highlighted by an NDA submission for zoliflodacin, the launch of ZEVTERA® in mid-2025, and continued growth of our marketed products, with U.S. net product sales forecasted to exceed $100 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925017461/tm257428d1_ex99-1.htm)) |
| May 7, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Calif. - May 7, 2025 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/tm2514212d1_ex99-1.htm)) |
| Jun 2025 | [NUZOLVENCE® (zoliflodacin) NDA/BLA acceptance](https://sec-api.dev/pdufa/zoliflodacin) | INVA |  | completed | "o In June 2025, the U.S. Food and Drug Administration (FDA) accepted the zoliflodacin New Drug Application (NDA), granted" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/tm2522376d1_ex99-1.htm)) |
| August 6, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Calif. - August 6, 2025 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2025, and highlighted select corporate progress and achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/tm2522376d1_ex99-1.htm)) |
| November 5, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925107014/tm2530226d1_ex99-1.htm)) |
| Dec 2025 | [NUZOLVENCE® (zoliflodacin) FDA approval](https://sec-api.dev/pdufa/zoliflodacin) | INVA |  | completed, approved | "Following the FDA approval of NUZOLVENCE® (formerly zoliflodacin) in December 2025, we started amortizing $2.6 million of the then in-process research and development as a marketed product over its estimated useful life." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1080014/000119312526447384/inva-20260930.htm)) |
| December 15, 2025 | [NUZOLVENCE® (zoliflodacin) PDUFA date](https://sec-api.dev/pdufa/zoliflodacin) | INVA |  | scheduled | "Zoliflodacin is currently under Priority Review by the FDA, with a Prescription Drug User Fee Act ("PDUFA") target action date of December 15, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1080014/000119312525267040/inva-20250930.htm)) |
| February 25, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/d23292dex991.htm)) |
| May 6, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/d54063dex991.htm)) |
| August 5, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/d228097dex991.htm)) |
| November 4, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526447366/d177079dex991.htm)) |

## Drugs

- [Carbapenem](https://sec-api.dev/pdufa/carbapenem): with carbapenem-resistant acinetobacter infections, with positive top-line data
- [ZEVTERA® (ceftobiprole)](https://sec-api.dev/pdufa/ceftobiprole): uncomplicated gonorrhea
- [Durlobactam](https://sec-api.dev/pdufa/durlobactam): 
- [Fluoroquinolone](https://sec-api.dev/pdufa/fluoroquinolone): 
- [XACDURO (xacduro)](https://sec-api.dev/pdufa/xacduro): 
- [NUZOLVENCE® (zoliflodacin)](https://sec-api.dev/pdufa/zoliflodacin): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/inva/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INVA catalysts: Innoviva, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/inva/catalysts

```bibtex
@misc{secapidev_companies_inva_catalysts_20261116,
  title        = {INVA catalysts: Innoviva, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/inva/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_inva_catalysts_20261116","title":"INVA catalysts: Innoviva, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/inva/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
